Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
0 hedge funds and large institutions have $0 invested in Interpace Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $58K → $0 (-$58K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$52K |
| 2 |
RG
Retirement Group
San Diego,
California
|
-$5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
IDXG Hedge Fund Activity: Q2 2021 in Review
0 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q2 2021, worth a combined $0 — down 100% from $58K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IDXG and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was HRT Financial, exiting entirely with an estimated $52K sold.
- 0 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q2 2021, down from 3 in Q1 2021.
- Funds reported $0 of Interpace Biosciences, Inc. Common Stock stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q2 2021 and 3 closed out, a net change of -3 holders.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q2 2021 was HRT Financial, an estimated $52K sold.
Based on aggregated 13F filings for Q2 2021.